FINWIRES · TerminalLIVE
FINWIRES

$IDYA

10 stories mentioning IDYA

Every FINWIRES story that references IDYA, newest first.

Wire

Update: IDEAYA Shares Fall After Pricing $300 Million Offering

(Updates with the latest stock price movement in the headline and the first paragraph.)IDEAYA Biosciences (IDYA) shares were down about 8% in Tuesday trading, a day after the company priced an underwritten public offering of securities to raise about $300 million.Late Monday, the firm said it is selling about 5.6 million shares at $27 each. It is also offering pre-funded warrants to buy around 5.6 million shares.IDEAYA said it has granted its underwriters a 30-day option to purchase up to about 1.7 million additional shares. The offering is expected to close on Wednesday.Price: $28.94, Change: $-2.54, Percent Change: -8.07%

$IDYA
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Inflation Data

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively traded Invesco QQQ Trust (QQQ) advanced 0.9% in Tuesday's premarket activity, amid key inflation data releasing this week.US stock futures were also higher, with S&P 500 Index futures up 0.5%, Dow Jones Industrial Average futures advancing 0.3%, and Nasdaq futures gaining 0.8% before the start of regular trading.The US trade deficit narrowed to $55.9 billion in April from $56.6 billion in March, coming in slightly below economists' expectations of a $56.1 billion gap.The existing home sales data for May and the wholesale inventory data for April will be released at 10:00 am ET.In premarket action, bitcoin was down by 1.2%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1% lower, Ether ETF (EETH) retreated by less than 1%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.05%, while the Vanguard Industrials Index Fund (VIS) retreated by 0.8% and the iShares US Industrials ETF (IYJ) was 0.9% higher.CECO Environmental (CECO) stock was up more than 10% before market open after the company said it now expects 2026 revenue of about $1.28 billion to $1.38 billion from its acquisition of Thermon Group, up from $940 million to $1 billion it projected previously.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.5%, the Vanguard Health Care Index Fund (VHT) was up 0.3%, while the iShares US Healthcare ETF (IYH) was flat. The iShares Biotechnology ETF (IBB) was 0.9% higher.IDEAYA Biosciences (IDYA) stock was down more than 7% premarket after the company said late Monday it priced an underwritten public offering expected to raise about $300 million in gross proceeds.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.2%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.7%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.7% lower.UBS Group (UBS) shares were up more than 2% pre-bell after Reuters reported that Swiss lawmakers are considering proposals that would reduce the capital burden facing UBS under planned banking reforms introduced after the collapse of Credit Suisse.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced 1.3%, and the iShares US Technology ETF (IYW) was 1.1% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 1.5%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased by 2.6%, while the iShares Semiconductor ETF (SOXX) rose by 2.5%.Cipher Digital (CIFR) shares were up more than 3% in premarket activity, following a 8.2% rise at the prior close. The company said late Monday that its Stingray Compute unit has priced an $810 million private offering of 6.0% senior secured notes due 2031 at 99.75% of face value.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.1% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 0.1%. The iShares US Consumer Staples ETF (IYK) retreated by 0.3%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) advanced 0.4%. The VanEck Retail ETF (RTH) increased by 0.7%, while the State Street SPDR S&P Retail ETF (XRT) was 0.5% higher.Carnival (CCL) shares were up more than 1% pre-bell after the company deployed Konami Gaming's Synkros casino management system across the Carnival Cruise Line fleet.EnergyThe iShares US Energy ETF (IYE) was down 0.9%, while the State Street Energy Select Sector SPDR ETF (XLE) retreated by 0.5%.Uranium Energy (UEC) stock was down more than 4% before the opening bell after the company reported a wider fiscal Q3 net loss.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 1.9% to $89.57 per barrel on the New York Mercantile Exchange. Natural gas was up 0.8% to $3.17 per 1 million British Thermal Units. The United States Oil Fund (USO) lost 2%, while the United States Natural Gas Fund (UNG) was 1.1% higher.Gold futures for July advanced by 0.1% to $4,365.80 an ounce on the Comex. Silver futures fell by 0.2% to $68.48 an ounce. SPDR Gold Shares (GLD) was up by 0.3%, and the iShares Silver Trust (SLV) increased by 0.7%.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$CCL$CECO$CIFR$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IDYA$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$PMR$QQQ$RTH$SLV$SOXX$SPY$UBS$UEC$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Wire

Ideaya Biosciences' Darovasertib Combination Data Profile is 'Highly Compelling,' Wedbush Says

Ideaya Biosciences' (IDYA) darovasertib plus crizotinib combination's overall data profile is "highly compelling" and data-to-date supports accelerated approval, Wedbush said in a Tuesday note.The company plans to submit its new drug application for darovasertib in H2 and has announced alignment with the US Food and Drug Administration to review the NDA under the real-time oncology review program, Wedbush noted.Outside of darovasertib, Wedbush said it is looking forward to a clinical update from ongoing Chinese studies investigating IDE849 by partner Jiangsu Hengrui at a medical conference in H2, as well as registrational trial initiations in 2027."We remain excited for the extensive clinical development across pipeline assets, as well as a nearing potential approval for darovasertib," Wedbush analysts said.The brokerage maintained the company's outperform rating with a $58 price target.Price: $28.01, Change: $-0.89, Percent Change: -3.08%

$IDYA
Wire

Ideaya Biosciences Moves Darovasertib Toward FDA Review After Positive Trial Readout

Ideaya Biosciences (IDYA) said the US Food and Drug Administration agreed to review its new drug application for darovasertib in combination with crizotinib for patients with first-line HLA*A2-negative metastatic uveal melanoma under the agency's Oncology Center of Excellence Real-Time Oncology Review program.The phase 2/3 trial of darovasertib in combination with crizotinib met its primary endpoint, lowering the risk of disease progression by 58% and achieving a statistically significant improvement in median progression-free survival of 6.9 months, Ideaya said Thursday in a statement.The company plans to begin submitting portions of its application in May and expects to complete the full filing in the H2.Price: $29.00, Change: $+0.95, Percent Change: +3.39%

$IDYA
Research

Update: Mizuho Keeps Price Target on IDEAYA Biosciences to $52, Maintains Outperform Rating

(Updated to keep price target unchanged).IDEAYA Biosciences (IDYA) has an average rating of buy and mean price target of $52.81, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $28.34, Change: $-0.73, Percent Change: -2.51%

$IDYA
Wire

Mizuho Adjusts Price Target on IDEAYA Biosciences to $52 From $46, Maintains Outperform Rating

IDEAYA Biosciences (IDYA) has an average rating of buy and mean price target of $52.81, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $28.33, Change: $-0.75, Percent Change: -2.56%

$IDYA
Wire

Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says

Ideaya Biosciences (IDYA) stock is not fully reflecting the strength of the data from the company's phase 2/3 trial evaluating darovasertib combined with crizotinib for metastatic uveal melanoma, RBC Capital Markets said in a note Monday.Analysts said they are "positive" on the meaningfulness of the data, the regulatory strategy for the new drug application in H2 of this year, and Ideaya's commercial positioning ahead of a 2027 launch.RBC said that the key opinion leaders invited to a call with the company were excited about the drug's ability to offer patients a high response rate and significant progression-free survival.Analysts said that the next key catalysts for the program include overall survival data and neo-adjuvant readouts, potentially in 2027.The ultimate overall survival readout is also likely to come in positive, they said.RBC has an outperform rating on the stock. It increased the price target to $53 from $49.Price: $31.24, Change: $-1.58, Percent Change: -4.81%

$IDYA
Wire

Wedbush Adjusts Price Target on IDEAYA Biosciences to $58 From $52, Maintains Outperform Rating

IDEAYA Biosciences (IDYA) has an average rating of buy and mean price target of $50.38, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $36.59, Change: $+6.09, Percent Change: +19.97%

$IDYA
Sectors

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

Health care stocks were mixed pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% lower and the iShares Biotechnology ETF (IBB) up 0.4%Spyre Therapeutics (SYRE) shares were up more than 29% after the company said its SPY001 investigational treatment for moderate-to-severely active ulcerative colitis met its primary and key secondary endpoints in a phase 2 trial.IDEAYA Biosciences (IDYA) stock was up more than 5% after the company said its phase 2/3 registrational trial evaluating darovasertib in combination with crizotinib in patients with metastatic uveal melanoma met its primary endpoint.Regeneron Pharmaceuticals (REGN) and Telix Pharmaceuticals (TLX) said they will jointly develop and commercialize next-generation radiopharmaceutical therapies. Telix Pharmaceuticals shares were up more than 5% premarket.

$IBB$IDYA$REGN$SYRE$TLX$XLV
Equities

Top Premarket Gainers

Sky Quarry (SKYQ) shares were up 48% in Monday premarket activity, continuing Friday's surge.Battalion Oil (BATL) stock was 32% higher, erasing the previous session's loss.Ideaya Biosciences (IDYA) shares were up 19% after the company said that its phase 2/3 registrational trial evaluating darovasertib in combination with crizotinib in patients with metastatic uveal melanoma met its primary endpoint.Leggett & Platt (LEG) stock was 7.2% higher after the company and Somnigroup International (SGI) said that Somnigroup has agreed to acquire Leggett & Platt in an all-stock transaction valued at about $2.50 billion.

$BATL$IDYA$LEG$SKYQ
IDYA News | FINWIRES